COMT inhibitors and liver toxicity.
Identifieur interne : 000139 ( Ncbi/Curation ); précédent : 000138; suivant : 000140COMT inhibitors and liver toxicity.
Auteurs : P. Watkins [États-Unis]Source :
- Neurology [ 0028-3878 ] ; 2000.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Benzophenones, Catechols.
- chemical , therapeutic use : Benzophenones, Catechols.
- chemical : Catechol O-Methyltransferase Inhibitors, Nitriles, Nitrophenols.
- drug effects : Liver.
- drug therapy : Parkinson Disease.
- Humans.
Abstract
This paper reviews the issue of hepatotoxicity with the use of the catechol-O-methly transferase (COMT) inhibitors tolcapone and entacapone. Neither drug caused hepatotoxicity in preclinical toxicity testing. However, in clinical trials of tolcapone, liver chemistry tests were elevated more than 3 times above the upper limit of normal in approximately 1% of patients who took the 100 mg dose and in approximately 3% of patients who took the 200 mg dose. These observations led to the recommendation that periodic monitoring of liver function be performed. Post-marketing surveillance studies noted 3 instances of acute liver failure with death after 60,000 patients had received tolcapone for a total of 40,000 patient-years. For this reason, the drug was withdrawn from the market in Europe and Canada, and a black box warning issued in the United States. In contrast, clinical trials with entacapone demonstrated no increase in liver enzymes above those observed with placebo. Further, no instances of acute liver failure or death attributed to the drug have been observed in post-marketing surveillance studies. Consequently, liver monitoring is not required with this agent. These data demonstrate that tolcapone is associated with a risk of hepatotoxicity but that no such risk has been detected with entacapone.
PubMed: 11147510
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001673
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001673
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001673
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000139
Links to Exploration step
pubmed:11147510Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COMT inhibitors and liver toxicity.</title><author><name sortKey="Watkins, P" sort="Watkins, P" uniqKey="Watkins P" first="P" last="Watkins">P. Watkins</name><affiliation wicri:level="1"><nlm:affiliation>University of North Carolina at Chapel Hill School of Medicine, 27599, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of North Carolina at Chapel Hill School of Medicine, 27599</wicri:regionArea><wicri:noRegion>27599</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:11147510</idno><idno type="pmid">11147510</idno><idno type="wicri:Area/PubMed/Corpus">001673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001673</idno><idno type="wicri:Area/PubMed/Curation">001673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001673</idno><idno type="wicri:Area/PubMed/Checkpoint">001673</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001673</idno><idno type="wicri:Area/Ncbi/Merge">000139</idno><idno type="wicri:Area/Ncbi/Curation">000139</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COMT inhibitors and liver toxicity.</title><author><name sortKey="Watkins, P" sort="Watkins, P" uniqKey="Watkins P" first="P" last="Watkins">P. Watkins</name><affiliation wicri:level="1"><nlm:affiliation>University of North Carolina at Chapel Hill School of Medicine, 27599, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of North Carolina at Chapel Hill School of Medicine, 27599</wicri:regionArea><wicri:noRegion>27599</wicri:noRegion></affiliation></author></analytic><series><title level="j">Neurology</title><idno type="ISSN">0028-3878</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benzophenones (adverse effects)</term><term>Benzophenones (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Catechols (adverse effects)</term><term>Catechols (therapeutic use)</term><term>Humans</term><term>Liver (drug effects)</term><term>Nitriles</term><term>Nitrophenols</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benzophenones</term><term>Catechols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzophenones</term><term>Catechols</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term><term>Nitriles</term><term>Nitrophenols</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Liver</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This paper reviews the issue of hepatotoxicity with the use of the catechol-O-methly transferase (COMT) inhibitors tolcapone and entacapone. Neither drug caused hepatotoxicity in preclinical toxicity testing. However, in clinical trials of tolcapone, liver chemistry tests were elevated more than 3 times above the upper limit of normal in approximately 1% of patients who took the 100 mg dose and in approximately 3% of patients who took the 200 mg dose. These observations led to the recommendation that periodic monitoring of liver function be performed. Post-marketing surveillance studies noted 3 instances of acute liver failure with death after 60,000 patients had received tolcapone for a total of 40,000 patient-years. For this reason, the drug was withdrawn from the market in Europe and Canada, and a black box warning issued in the United States. In contrast, clinical trials with entacapone demonstrated no increase in liver enzymes above those observed with placebo. Further, no instances of acute liver failure or death attributed to the drug have been observed in post-marketing surveillance studies. Consequently, liver monitoring is not required with this agent. These data demonstrate that tolcapone is associated with a risk of hepatotoxicity but that no such risk has been detected with entacapone.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000139 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:11147510
|texte= COMT inhibitors and liver toxicity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:11147510" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |